CClinicalTrials.gg
Status unknownNCT03888625Updated Mar 25, 2019

Compare the Healing Process of Idiopathic Macular Hole With Different Surgical Techniques

An interventional study of Conventional ILM Peeling and Inverted ILM Peeling in Macular Holes, sponsored by Federal University of São Paulo. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-25.

Sponsored by Federal University of São Paulo · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2018, registered Mar 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To compare anatomic and functional results, and to evaluate postoperatively the healing process in 2 different techniques for the closure of the macular holes (MH)

Read the detailed description

Patients with macular holes classified in stages 3 and 4 will be randomized into 2 groups. . In Group A, patients will undergo peeling with complete removal of the internal limiting membrane (ILM) and in the group B, the inverted ILM peeling technique will be performed. The 20% sulfur hexafluoride (SF6) gas will be used as a tamponade agent in all surgeries, and patients will be instructed to avoid the prone position for 5 days.

OCT images will be performed in the first 5 postoperative days and months 1, 3 and 6.

The primary outcome is anatomic closure of the MH closure in the month 6. The second outcomes are: mean best corrected visual acuity (BCVA) at month 6, mean change in the BCVA at month 6; integrity of the perifoveal external limiting membrane and ellipsoid zone on Optical Coherence Tomography (OCT); MH closure rate over time in days; functional improvement of microperimetry Statistical analysis will be performed with Student t-test and the p-value of ≤ 0.05 is considered significant.

02

Conditions studied

  • Macular Holes

Browse trials for

Keywords

  • macular holes
03

In context

Retinal Perforations

156 studies on the registry are indexed under Retinal Perforations; 21 are open to participants now.

This study's planned enrollment of 60 is above the median of 44 across 104 interventional studies indexed under Retinal Perforations.

Browse Retinal Perforations studies →

Lead sponsor

Federal University of São Paulo is the lead sponsor of 427 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

> Stage 3 and 4 macular holes with visual acuity between 20/30 and 20/800 according to the ETDRS chart.

Exclusion criteria

Exclusion Criteria:

  • Macular holes secondary to ocular trauma, myopia or retinal detachment
  • Any previous treatment for the macular hole
  • Evidence on examination of any diabetic retinopathy
  • History or presence of wet or dry age macular degeneration (AMD)
  • Presence of epiretinal membrane or prior uveitis
  • Any ocular surgery within 3 months before baseline
  • Intra or periocular infection
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Group A: Conventional ILM peeling

    peeling with complete removal of the internal limiting membrane (ILM)

    Procedure: Conventional ILM Peeling

  • Active comparator
    GroupB: Inverted ILM Peeling

    the inverted ILM peeling technique, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange

    Procedure: Inverted ILM Peeling

Interventions

  • ProcedureConventional ILM Peeling

    peeling with complete removal of the internal limiting membrane (ILM)

  • ProcedureInverted ILM Peeling

    the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange

06

What researchers measure

Primary outcomes

  1. Rate of Anatomic closure

    Rate of anatomic macular hole closure in the OCT at month 6

    Time frame: Month 6 post operative

Secondary outcomes

  1. BCVA mean

    mean best corrected visual acuity (BCVA) at month 6

    Time frame: Month 6 post operative

  2. BCVA change

    change in the BCVA at month 6

    Time frame: Screening and Month 6 post operative

  3. Integrity Membrane measured in microns (μm) by OCT

    In the month 6, the area of discontinuity of the perifoveal external limiting membrane and ellipsoid zone in the OCT images will be measured in microns (μm) and correlated between groups

    Time frame: Month 6 post operative

07

Study locations

1 of 1 sites recruiting
  • Dept. of Ophthalmology
    São Paulo, 04023-062, Brazil
    • Mauricio Maia, MD, PhD · Contact · maiamauricio@terra.com.br · 1155764848
    • Luci p Silva, PhD, MBA · Contact · luci.pesquisa@gmail.com · 11971571967
    • Luiz Felipe A Lucatto, MD · Principal investigator
    • Octaviano Magalhães Júnior, PhD, MD · Sub investigator
    • Felipe Muralha, MD · Sub investigator
    • Alex Grupenmacher, MD · Sub investigator
    • Francisco Stefanini, MD · Sub investigator
    • Muller G Urias, MD · Sub investigator
    • Maia Mauricio, PhD, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03888625
Lead sponsor
Federal University of São Paulo
Responsible party
Mauricio Maia (Professor of Ophthalmology Dept, Federal University of São Paulo) — Principal investigator
First posted
Mar 25, 2019
Start date
Jun 15, 2018
Primary completion
Jun 15, 2020 (estimated)
Completion
Jun 30, 2020 (estimated)
Last update
Mar 25, 2019

Study contacts

Mauricio Maia, MD, PhD
Contact
maiamauricio@terra.com.br
+55-18-991137727
Luci p Silva, PhD, MBA
Contact
luci.pesquisa@gmail.com
11971571967
Mauricio Maia, MD, PhD
study director · Federal University of São Paulo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion